Opus Genetics (Nasdaq: IRD), a clinical-stage biopharmaceutical company focused on gene therapies for inherited retinal diseases, announced that management will present at the RBC Capital Markets 2026 Global Healthcare Conference on Tuesday, May 19, 2026 at 11:00 a.m. ET.
A live and archived webcast will be available via the Investors > Events section of the Opus Genetics website.
Loading...
Loading translation...
Positive
None.
Negative
None.
News Market Reaction – IRD
-2.90%
-2.90%Session close to close
In the May 13 session, IRD declined 2.90%, reflecting a moderate negative market reaction.
This announcement adds another investor-relations touchpoint as Opus presents at a major healthcare ...
Analysis
This announcement adds another investor-relations touchpoint as Opus presents at a major healthcare conference on May 19, 2026. It follows recent earnings, multiple SEC filings, expanded financing capacity, and active clinical progress in LCA5 and BEST1 programs. Investors may watch for any new disclosures or guidance during the presentation, while keeping in view the effective resale registration for 7,374,632 shares and the company’s history of mixed price reactions to otherwise constructive news.
Planned presentations at multiple ophthalmology and gene-therapy meetings.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
News has produced mixed reactions: positive clinical and regulatory updates sometimes saw selloffs, while enrollment and earnings/pipeline updates more often aligned with modest gains.
Recent Company History
Over the last few weeks, Opus announced multiple catalysts. On May 12, Q1 2026 earnings and pipeline milestones followed prior SEC filings detailing higher R&D spend and a larger non-cash warrant loss. Earlier in May, the company completed Cohort 1 enrollment in its OPGx-BEST1 Phase 1/2 study and presented encouraging ARVO 2026 clinical data across LCA5, BEST1, and RHO programs. FDA acceptance of OPGx-LCA5 into the RDEP program and participation in major ophthalmology meetings underscored an active development and visibility push, to which today’s investor conference appearance directly relates.
"a clinical-stage biopharmaceutical company developing gene therapies to restore vision"
Gene therapies are medical treatments that change or replace a person’s genetic instructions to fix or counteract a disease, using biological delivery methods to get the new material into cells — like repairing or swapping pages in a faulty instruction manual. They matter to investors because they can offer one-time or long-lasting cures with large market potential, but carry high development costs, regulatory scrutiny and manufacturing challenges that make outcomes binary and investment risky.
inherited retinal diseasesmedical
"prevent blindness in patients with inherited retinal diseases (IRDs)"
Inherited retinal diseases are a group of genetic conditions in which errors in the genes that build and maintain the light-sensing cells at the back of the eye cause progressive vision loss or blindness; think of it as faulty wiring in a camera that gradually degrades the picture. They matter to investors because they define a clear patient population with high unmet need, driving demand for diagnostics and novel treatments (gene, cell or drug therapies) that can produce long-term revenue, regulatory milestones and intellectual property value.
webcasttechnical
"A link to the live and archived webcast may be accessed on Opus Genetics’ website"
A webcast is a live or recorded online event where people watch or listen to presentations, announcements, or performances through the internet. It’s like a TV broadcast but over the internet, allowing viewers from anywhere to tune in in real time or later. Webcasts are important because they let companies share information quickly and widely with audiences around the world.
RESEARCH TRIANGLE PARK, N.C., May 13, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), announced today that management will present at the RBC Capital Markets 2026 Global Healthcare Conference on Tuesday, May 19, 2026 at 11:00 a.m. ET.
A link to the live and archived webcast may be accessed on Opus Genetics’ website under the Investors section: Events.
About Opus Genetics
Opus Genetics is a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs). The Company is developing durable, one-time treatments designed to address the underlying genetic causes of severe retinal disorders. The Company’s pipeline includes seven AAV-based programs, led by OPGx-LCA5 for LCA5-related mutations and OPGx-BEST1 for BEST1-related retinal degeneration, with additional candidates targeting RDH12, MERTK, RHO, CNGB1 and NMNAT1. The Company is based in Research Triangle Park, NC. For more information, visit www.opusgtx.com.
Contacts:
Investors Jenny Kobin Remy Bernarda IR Advisory Solutions ir@opusgtx.com
When will Opus Genetics (Nasdaq: IRD) present at the RBC Capital Markets 2026 Global Healthcare Conference?
Opus Genetics will present on Tuesday, May 19, 2026 at 11:00 a.m. ET. According to the company, this session is part of the RBC Capital Markets 2026 Global Healthcare Conference and will feature remarks from Opus management for investors.
How can investors access the Opus Genetics (IRD) webcast for the May 19, 2026 RBC conference presentation?
Investors can access the Opus Genetics webcast through the Investors section of the company’s website under Events. According to Opus Genetics, both a live webcast and an archived replay of the May 19, 2026 presentation will be available online.
What type of company is Opus Genetics (IRD) participating in the 2026 RBC Global Healthcare Conference?
Opus Genetics is a clinical-stage biopharmaceutical company developing gene therapies for inherited retinal diseases. According to the company, its programs aim to restore vision and prevent blindness, and the RBC Capital Markets 2026 Global Healthcare Conference appearance provides a platform to update investors.
Where is Opus Genetics headquartered and how is this relevant to its 2026 RBC conference appearance?
Opus Genetics is headquartered in Research Triangle Park, North Carolina. According to the company, its participation in the RBC Capital Markets 2026 Global Healthcare Conference allows management to highlight its gene therapy pipeline for inherited retinal diseases to a broad healthcare investor audience.
Will a replay of the Opus Genetics (IRD) May 19, 2026 RBC conference presentation be available to investors?
Yes, a replay will be available as an archived webcast. According to Opus Genetics, investors can access the archived presentation after the event via the company’s website, under the Investors section labeled Events, alongside the live webcast link.
Why might Opus Genetics’ appearance at the RBC Capital Markets 2026 Global Healthcare Conference interest IRD shareholders?
The conference appearance offers shareholders direct insight into Opus Genetics’ management commentary. According to the company, the webcast gives investors convenient access to its narrative on gene therapy programs for inherited retinal diseases and overall corporate strategy on May 19, 2026.
